Evidence map›Paper›PMID 41120707›Full record

ArticleJournal of neurology2025

Determinants of cerebral amyloid angiopathy progression: a multicenter retrospective study.

Payam Tabaee Damavandi, Giulia Negro, Slaven Pikija, Benedetta Storti, Andreas Charidimou, Bassam Al-Fatly, Andreea Toma, Giulia Marinoni, Giorgia Orsani, Anna Bersano and 1 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Payam Tabaee Damavandi *Department of Neurology, Fondazione IRCCS San Gerardo Dei Tintori, Via Pergolesi, 33, 20052, Monza, Italy.
Giulia Negro *Department of Neurology, Fondazione IRCCS San Gerardo Dei Tintori, Via Pergolesi, 33, 20052, Monza, Italy.
Slaven PikijaDepartment of Neurology, Christian Doppler University Hospital, Salzburg, Austria.
Benedetta StortiCerebrovascular Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Andreas CharidimouDepartment of Neurology, Boston University Medical Center, Boston University School of Medicine, Boston, MA, USA.
Bassam Al-FatlyDepartment of Neurology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany.
Andreea TomaDepartment of Neurology, Christian Doppler University Hospital, Salzburg, Austria.
Giulia MarinoniCerebrovascular Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Giorgia OrsaniDepartment of Neurology, Fondazione IRCCS San Gerardo Dei Tintori, Via Pergolesi, 33, 20052, Monza, Italy.
Anna BersanoCerebrovascular Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Jacopo C DiFrancescoDepartment of Neurology, Fondazione IRCCS San Gerardo Dei Tintori, Via Pergolesi, 33, 20052, Monza, Italy. jacopo.difrancesco@unimib.it.ORCID http://orcid.org/0000-0002-4102-1188

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveCerebral amyloid angiopathy (CAA) is a major cause of lobar intracerebral hemorrhage and cognitive decline in older adults. Imaging biomarkers as lobar cerebral microbleeds (CMBs) and cortical superficial siderosis (cSS) are characteristic of the disease, whose longitudinal evolution and clinical implications remain unclear. This study investigated predictors of radiological progression and their association with recurrent intracranial hemorrhage and mortality.

methodsWe retrospectively included patients with a diagnosis of CAA, according to Boston criteria version 2.0, from three European centers. Radiological progression was defined as the appearance of new CMBs or cSS during follow-up. The primary outcome was recurrent intracranial hemorrhage; the secondary outcome was all-cause mortality.

resultsNinety-two patients were included (73 with hemorrhagic, 19 with non-hemorrhagic presentations), with a median follow-up of 34.3 months (IQR: 12.8-66.6). CMB progression occurred in 30% of patients and resulted severe cases in 15%. cSS increased in prevalence from 66% at baseline to 83% at follow-up. Baseline CMBs (OR 9.33, p < 0.001) and cSS (OR 5.94, p = 0.01) predicted their respective progression. Recurrent intracranial hemorrhage occurred in 51% and was associated with the presence of baseline cSS (OR 3.38, p = 0.046) and hemorrhagic presentation at onset (OR 4.97, p = 0.02). Overall mortality was 27%, with no significant radiological predictors identified. Radiological progression was not associated with clinical outcomes.

conclusionCMBs and cSS are dynamic markers in CAA, with baseline presence predicting their progression. While repeat brain MRI may aid in disease monitoring, radiological progression alone does not predict clinical events.

Indexed as

Cerebral Amyloid AngiopathyCerebral HemorrhageDisease ProgressionSiderosisAgedAged, 80 and overFemaleFollow-Up StudiesHumansMagnetic Resonance ImagingMaleMiddle AgedRetrospective StudiesAmyloid-βBleedingCerebral amyloid angiopathyHemorrhageMRIProgression

Identifiers

PMID41120707

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.